Orthofix International N.V. Stock Downgraded (OFIX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Orthofix International N.V (Nasdaq: OFIX) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • ORTHOFIX INTERNATIONAL NV has improved earnings per share by 19.4% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, ORTHOFIX INTERNATIONAL NV turned its bottom line around by earning $2.78 versus -$0.16 in the prior year. This year, the market expects an improvement in earnings ($2.97 versus $2.78).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 65.5% when compared to the same quarter one year prior, rising from $12.39 million to $20.51 million.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market on the basis of return on equity, ORTHOFIX INTERNATIONAL NV has underperformed in comparison with the industry average, but has exceeded that of the S&P 500.
  • OFIX has underperformed the S&P 500 Index, declining 21.24% from its price level of one year ago. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • Net operating cash flow has significantly decreased to -$57.19 million or 327.07% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
.

Orthofix International N.V., a medical device company, designs, develops, manufactures, markets, and distributes medical equipment used principally by musculoskeletal medical specialists for spine and orthopedic applications. The company operates through two segments, Spine and Orthopedics. The company has a P/E ratio of 11.5, below the S&P 500 P/E ratio of 17.7. Orthofix International N.V has a market cap of $620.6 million and is part of the health care sector and health services industry. Shares are down 18.3% year to date as of the close of trading on Monday.

You can view the full Orthofix International N.V Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

6 Stocks Trading Up With Unusual Volume

6 Stocks Trending Up With Major Volume

Strong And Under The Radar: Orthofix International (OFIX)

Where Will a Healthy Zimmer Biomet Turn Next for Acquisitions?

Zimmer Biomet and NuVasive Could be a Spine-Tingling Combination